| Dr Edward Cottle, MD | |
|
7007 Powers Blvd, Parma, OH 44129-5437 | |
| (440) 743-4356 | |
| Not Available |
| Full Name | Dr Edward Cottle |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 7007 Powers Blvd, Parma, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477538445 | NPI | - | NPPES |
| 0427541 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35042014 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward Cottle, MD Po Box 29220, Parma, OH 44129-0220 Ph: (800) 288-8325 | Dr Edward Cottle, MD 7007 Powers Blvd, Parma, OH 44129-5437 Ph: (440) 743-4356 |
News Archive
Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced three new studies that demonstrate the clinical utility of PillCam SB capsule endoscopy in providing physicians with critical information on how they manage and/or diagnose intestinal disorders. These novel studies were carried out in pediatric patients with gastrointestinal symptoms, including children with known or suspected Crohn's disease.
Better use of standard assessment tools could help long-term care homes identify which new residents are at risk of hospitalization or death in the first 90 days of admission.
Charles Ebikeme, a writer who "has worked for many years as a research scientist on African sleeping sickness" examines a health revolution in information and communications technology (ICT) taking place across the developing world in this "End the Neglect" blog post, writing, "The initial concept of telemedicine now spans a wide spectrum of applications, labels, contexts, and platforms."
Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.
Toxicology as a science has not evolved to keep pace with the chemical revolution, according to Thomas Hartung writing in the International Journal of Risk Assessment and Management, Hartung highlights ten problems that must be addressed if toxicology is to be made fit for purpose in the 21st Century.
› Verified 4 days ago
Candace A Rich, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7007 Powers Blvd, Parma, OH 44129 Phone: 440-743-3000 | |
Dr. Mian Mueenuddin, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-524-7377 Fax: 216-479-5554 | |
Dr. Caroline G Steinetz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 7007 Powers Blvd, Parma, OH 44129 Phone: 440-743-4356 | |
Yomna Amer, Pathology Medicare: Not Enrolled in Medicare Practice Location: 3343 Lincoln Ave, Parma, OH 44134 Phone: 781-742-0343 | |
Dr. Wendy Ann Chamberlain, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 5850 Ridge Rd, Parma, OH 44129 Phone: 513-834-7063 |